Metastatic Colorectal Cancer. Real-World Data Analysis.

Istanbul Medeniyet University1,750 enrolled

Overview

The Treatment Choices, Duration and Outcomes in Patients with Ras Wild Type (RAS WT) Metastatic Colorectal Cancer (mCRC). Retrospective, Multi-Center, Real-World Data Analysis

In this study, with the given rationale is to reveal treatment approaches, survival data, side effect profile and their management in our country in RAS WT mCRC patients by means of the real-world data collection.

Study Type

OBSERVATIONAL

Enrollment

1,750

Conditions

Metastatic Colorectal Cancer

Eligibility

Sex: ALLMin age: 18 YearsMax age: 99 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Patients who have been histologically diagnosed with mCRC 2. Patients over the age of 18 3. Patients receiving at least a cycle systemic treatment for metastatic disease 4. RAS wild type patients 5. Patients who has demographic, histopathological and clinical information Exclusion Criteria: 1. Patients diagnosed as mCRC but only referred to BSC 2. Patients with RAS mutation 3. Patients who were included in any clinical trial except standard treatments during their treatment

Locations (1)

Istanbul Medeniyet University Hospital

Istanbul, Turkey (Türkiye)

Outcomes

Primary Outcomes

Percentage of use anti-EGFR agents

The anti-EGFR agent selection

Time frame: throughout of treatment, 3 years

Progression Free Survival (PFS)

PFS three years after initiation of treatment with anti-EGFR agents

Time frame: 3 years treatment

Secondary Outcomes

Advers events

Advers event of anti EGFR is defined as any untoward or unfavourable medical occurrence, including any abnormal sign, symptom, or disease, temporally associated with the patient's participation. The CTCAE v.4.0 will use in this research.

Time frame: throughout of treatment, 3 years

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.